CRSP - CRISPR Therapeutics AG Stock Price & Dividend Safety Sector: Healthcare | Exchange: NASDAQ Global Market Current Price & Safety Score Price: 49.01 USD StockBonds Safety Grade: D Altman Z-Score (Bankruptcy Risk): 2.46 StockBond Score: -2.71 Company Description CRISPR Therapeutics AG CRSP is a biotechnology firm dedicated to pioneering genebased medicines for severe diseases The company achieves this through its exclusive Clustered Regularly Interspaced Short Palindromic Repeats CRISPRCRISPRassociated protein 9 Cas9 technology which enables precise and targeted alterations to an organisms genetic code Its extensive pipeline includes therapeutic candidates spanning multiple medical areas such as blood disorders hemoglobinopathies various cancers oncology regenerative medicine and rare conditions The companys flagship investigational therapy is CTX001 an ex vivo CRISPR geneedited treatment This therapy aims to benefit patients with transfusiondependent betathalassemia or severe sickle cell disease by modifying their own hematopoietic stem cells to markedly boost the production of fetal hemoglobin within red blood cells CRISPR Therapeutics is also advancing several other genetically engineered allogeneic donorsourced CART investigational therapies CTX110 designed to combat cluster of differentiation 19positive malignancies CTX120 which targets Bcell maturation antigen for multiple myeloma that has relapsed or proven resistant to previous treatments and CTX130 focused on Cluster of Differentiation 70 for a spectrum of solid tumors and blood cancers Furthermore the company is developing VCTX210 an immuneevasive geneedited stem cellderived product candidate for treating type 1 diabetes It is also pursuing various in vivo geneediting initiatives aimed at addressing disorders affecting the liver lungs muscles and central nervous system The company has forged strategic alliances with significant partners including Bayer Healthcare LLC Vertex Pharmaceuticals Incorporated ViaCyte Inc Nkarta Inc and Capsida Biotherapeutics CRISPR Therapeutics AG was established in 2013 and maintains its headquarters in Zug Switzerland